President Donald J. Trump is set on revitalizing the American pharmaceutical and biotechnology sectors, framing it as a dual imperative of national security and a catalyst for extraordinary economic growth for American laborers.
In this context, Gilead Sciences has recently joined the ranks of industry frontrunners by announcing a substantial $11 billion investment aimed at bolstering its U.S. operations.
This move aligns with a broader trend as several key players in the industry ramp up their domestic investments to support President Trump’s ambitious vision:
- Based in New Jersey, Johnson & Johnson has pledged a whopping $55 billion towards manufacturing, research and development, and technological innovations in the next four years.
- Roche, the Swiss pharmaceuticals giant, has committed to a staggering $50 billion infusion into its U.S.-based manufacturing and research sectors.
- Also hailing from New Jersey, Bristol Myers Squibb has made headlines with a $40 billion investment in research, development, technology, and manufacturing.
- Eli Lilly and Company, based in Indiana, has announced a $27 billion investment with plans to more than double its domestic manufacturing capacity.
- Swiss drugmaker Novartis has outlined a $23 billion investment aimed at either building or expanding ten manufacturing facilities across the U.S.
- Illinois-based AbbVie has declared a $10 billion commitment over the next decade to support growth and establish four new manufacturing plants within its network.
- New Jersey’s Merck & Co. has stated it will invest $9 billion over the next few years following the inauguration of a new $1 billion manufacturing facility in North Carolina, which includes a state-of-the-art biologics manufacturing plant in Delaware.
- Merck Animal Health has also announced an $895 million investment to enhance their manufacturing operations in Kansas.
- Regeneron Pharmaceuticals, based in New York, has secured a $3 billion agreement with FUJIFILM Diosynth Biotechnologies to bolster drug production at its facility in North Carolina.
- California’s Amgen has laid out plans for a $900 million investment to expand its manufacturing operation in Ohio, promising the creation of 350 new jobs.
- Lastly, Abbott Laboratories from Illinois has declared a $500 million investment targeting enhancements at their facilities in Illinois and Texas.
